The negative impact of antibiotic resistance

Clinical Microbiology and Infection

Volumn 22, Issue 5, 2016, Pages 416-422

  Friedman, N D ^a   Temkin, E ^b   Carmeli, Y ^b  

^a BARWON HEALTH   (Australia)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Antibiotic; Antimicrobial; Infection; Resistance; Selective pressure

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ADVERSE OUTCOME; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; BACTERIAL VIRULENCE; BACTERIUM; DISEASE SEVERITY; HEALTH CARE; HEALTH CARE SYSTEM; HUMAN; INFECTION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; BACTERIAL INFECTIONS; ECONOMICS; HEALTH CARE COST; MICROBIOLOGY; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; HEALTH CARE COSTS; HUMANS; TREATMENT FAILURE;

EID: 84969540564     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2015.12.002     Document Type: Review

References (48)

1. Bartlett J.G., Mundy L.M. Community-acquired pneumonia. N Engl J Med 1995, 333:1618-1624.
2. Karchmer A.W. Staphylococcus aureus and Vancomycin: the Sequel. Ann Intern Med 1991, 115:739-741.
3. Newman W., Torres J.M., Guck J.K. Bacterial endocarditis: an analysis of fifty-two cases. Am J Med 1954, 16:535-542.
4. Hirsch E.F. The treatment of infected wounds, Alexis Carrel's contribution to the care of wounded soldiers during world war I. J Trauma Acute Care Surg 2008, 64:S209-S210.
5. Hawkey P.M. The growing burden of antimicrobial resistance. J Antimicrob Chemother 2008, 62(s1):i1-i9.
6. Mouton J.W., Brown D.F.J., Apfalter P., Cantón R., Giske C.G., Ivanova M., et al. The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach. Clin Microbiol Infect 2012, 18:E37-E45.
7. Holmes N.E., Turnidge J.D., Munckhof W.J., Robinson J.O., Korman T.M., O'Sullivan M.V.N., et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis 2011, 204:340-347.
8. Yu V.L., Chiou C.C.C., Feldman C., Ortqvist A., Rello J., Morris A.J., et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003, 37:230-237.
9. Shlaes D.M., Gerding D.N., John J.F., Craig W.A., Bornstein D.L., Duncan R.A., et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997, 25:584-599.
10. Bolhofer W.A., Sheehan J.C., Abrams E.L.A. Totally synthetic penicillins. J Am Chem Soc 1960, 82:3437-3441.
11. Enright M.C., Robinson D.A., Randle G., Feil E.J., Grundmann H., Spratt B.G. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci USA 2002, 99:7687-7692.
12. Eliopoulos G.M., Cosgrove S.E., Carmeli Y. The impact of antibacterial resistance on health and economic outcomes. Clin Infect Dis 2003, 36:1433-1437.
13. Cosgrove S.E., Sakoulas G., Perencevich E.N., Schwaber M.J., Karchmer A.W., Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003, 36:53-59.
14. Engemann J.J., Carmeli Y., Cosgrove S.E., Fowler V.G., Bronstein M.Z., Trivette S.L., et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003, 36:592-598.
15. Melzer M., Petersen I. Mortality following bacteraemic infection caused by extended spectrum β-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect 2007, 55:254-259.
16. Schwaber M.J., Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum β-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007, 60:913-920.
17. Rottier W.C., Ammerlaan H.S.M., Bonten M.J.M. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother 2012, 67:1311-1320.
18. Borer A., Saidel-Odes L., Riesenberg K., Eskira S., Peled N., Nativ R., et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 2009, 30:972-976.
19. Patel G., Huprikar S., Factor S.H., Jenkins S.G., Calfee D.P. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008, 29:1099-1106.
20. Nutman A., Glick R., Temkin E., Hoshen M., Edgar R., Braun T., et al. A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia. Clin Microbiol Infect 2014, 20:O1028-O1034.
21. Metlay J.P., Hofmann J., Cetron M.S., Fine M.J., Farley M.M., Whitney C., et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000, 30:520-528.
22. Unemo M., Shafer W.M. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev 2014, 27:587-613.
23. Williamson D.A., Barrett L.K., Rogers B.A., Freeman J.T., Hadway P., Paterson D.L. Infectious complications following transrectal ultrasound-guided prostate biopsy: new challenges in the era of multidrug-resistant Escherichia coli. Clin Infect Dis 2013, 57:267-274.
24. Wagenlehner F.M.E., van Oostrum E., Tenke P., Tandogdu Z., Çek M., Grabe M., et al. Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol 2013, 63:521-527.
25. Kim J., Kang C.-I., Joo E.-J., Ha Y.E., Cho S.Y., Gwak G.-Y., et al. Risk factors of community-onset spontaneous bacterial peritonitis caused by fluoroquinolone-resistant Escherichia coli in patients with cirrhosis. Liver Int 2014, 34:695-699.
26. Lautenbach E., Baldus Patel J., Bilker W.B., Edelstein P.H., Fishman N.O. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001, 32:1162-1171.
27. Daikos G.L., Petrikkos P., Psichogiou M., Kosmidis C., Vryonis E., Skoutelis A., et al. Prospective observational study of the impact of VIM-1 metallo-β-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother 2009, 53:1868-1873.
28. Acar J.F. Consequences of bacterial resistance to antibiotics in medical practice. Clin Infect Dis 1997, 24(S1):S17-S18.
29. Ben-David D., Kordevani R., Keller N., Tal I., Marzel A., Gal-Mor O., et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect 2012, 18:54-60.
30. Bogan C., Kaye K.S., Chopra T., Chopra T., Hayakawa K., Pogue J.M., et al. Outcomes of carbapenem-resistant Enterobacteriaceae isolation: matched analysis. Am J Infect Control 2014, 42:612-620.
31. Paterson D.L. Impact of antibiotic resistance in gram-negative bacilli on empirical and definitive antibiotic therapy. Clin Infect Dis 2008, 47. S1:S14-20.
32. Freifeld A.G., Bow E.J., Sepkowitz K.A., Boeckh M.J., Ito J.I., Mullen C.A., et al. Clinical practice guideline for the use of antibacterial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011, 52:e56-e93.
33. Doern G.V., Heilmann K.P., Huynh H.K., Rhomberg P.R., Coffman S.L., Brueggemann A.B. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob Agents Chemother 2001, 45:1721-1729.
34. McMaster P., McIntyre P., Gilmour R., Gilbert L., Kakakios A., Mellis C. The emergence of resistant pneumococcal meningitis-implications for empiric therapy. Arch Dis Childhood 2002, 87:207-210.
35. Michalopoulos A.S., Tsiodras S., Rellos K., Mentzelopoulos S., Falagas M.E. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005, 11:115-121.
36. Falagas M.E., Kasiakou S.K., Saravolatz L.D. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005, 40:1333-1341.
37. Tzouvelekis L.S., Markogiannakis A., Psichogiou M., Tassios P.T., Daikos G.L. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 2012, 25:682-707.
38. Wyllie D.H., Crook D.W., Peto T.E. Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997-2003: cohort study. BMJ 2006, 333:281.
39. Wassenberg M.W., De Wit G.A., Van Hout B.A., Bonten M.J. Quantifying cost-effectiveness of controlling nosocomial spread of antibiotic-resistant bacteria: the case of MRSA. PloS One 2010, 5:e11562.
40. Johnson P.D.R., Ballard S.A., Grabsch E.A., Stinear T.P., Seemann T., Young H.L., et al. A sustained hospital outbreak of vancomycin-resistant Enterococcus faecium bacteremia due to emergence of vanB E. faecium sequence type 203. J Infect Dis 2010, 202:1278-1286.
41. Teillant A., Gandra S., Barter D., Morgan D.J., Laxminarayan R. Potential burden of antibiotic resistance on surgery and cancer chemotherapy antibiotic prophylaxis in the USA: a literature review and modelling study. Lancet Infect Dis 2015, 10.1016/S1473-3099(15)00270-4.
42. Girmenia C., Rossolini G.M., Piciocchi A., Bertaina A., Pisapia G., Pastore D., et al. Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy. Bone Marrow Transplant 2015, 50:282-288.
43. McCann S., Byrne J.L., Rovira M., Shaw P., Ribaud P., Sica S., et al. Outbreaks of infectious diseases in stem cell transplant units: a silent cause of death for patients and transplant programmes. Bone Marrow Transplant 2004, 33:519-529.
44. Courtney J.M., Dunbar K.E., McDowell A., Moore J.E., Warke T.J., Stevenson M., et al. Clinical outcome of Burkholderia cepacia complex infection in cystic fibrosis adults. J Cyst Fibros 2004, 3:93-98.
45. Alexander B.D., Petzold E.W., Reller L.B., Palmer S.M., Davis R.D., Woods C.W., et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant 2008, 8:1025-1030.
46. OECD (2015) Antimicrobial Resistance in G7 countries and beyond: Economic Issues, Policies and Options for Action 2015, Available at:. http://www.oecd.org/els/health-systems/antimicrobial-resistance.htm.
47. Macrae M.B., Shannon K.P., Rayner D.M., Kaiser A.M., Hoffman P.N., French G.L. A simultaneous outbreak on a neonatal unit of two strains of multiply antibiotic resistant Klebsiella pneumoniae controllable only by ward closure. J Hosp Infect 2001, 49:183-192.
48. Boucher H.W., Talbot G.H., Benjamin D.K., Bradley J., Guidos R.J., Jones R.N., et al. 10×'20 progress-development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013, Infectious Diseases Society of America, cit152.